Skip to main content
. 2016 Mar 29;11(3):e0151815. doi: 10.1371/journal.pone.0151815

Fig 2. Kaplan-Meier plots of progression-free and overall survival duration in patients with primary GBM.

Fig 2

(A, B) Kaplan–Meier survival analysis of PFS and OS duration in 78 primary GBM patients according to MMP9 mRNA expression. Patients with low MMP9 expression had a longer OS and PFS than patients with high MMP9 expression (p = 0.0012 and p = 0.0066, respectively). (C, D) Two independent datasets (REMBRANDT and GSE16011) were used to validate the association between MMP9 expression and survival. Patients with lower MMP9 expression also had improved OS in the two validation datasets (p = 0.0338 and p<0.0001, respectively).